[
  {
    "text": "THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REOUEST. REDACTED MATERIAL IS",
    "bbox": [
      127,
      84,
      1000,
      94
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "NOISSINNON HNNVHMXA NNV SAILINNMIS HHL HLIM ARALVNVHIS CITI NAGN RRH NNV I*   HLIM HIIVN",
    "bbox": [
      192,
      100,
      1000,
      111
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "common control') shall mean: (a) ownership of at least fifty percent (50%) of the equity capital or other ownership interest in or of an entity; (b) the",
    "bbox": [
      111,
      130,
      1000,
      142
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "power to control or otherwise direct the affairs of an entity; (c) in the case of non-stock organizations, the power to control the distribution of",
    "bbox": [
      110,
      144,
      1000,
      159
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "profits of an entity; or (d) such other relationship as, in fact, results in actual control over the management, business, and affairs of an entity;",
    "bbox": [
      112,
      162,
      1000,
      174
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "b) \"Agreement' means this Supply Agreement for the Product, including all Exhibits attached hereto;",
    "bbox": [
      111,
      193,
      871,
      206
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "c) \"Applicable Law\"' means any applicable law, statute, rule, regulation, order, judgment or ordinance of any governmental or regulatory authority or",
    "bbox": [
      113,
      226,
      1000,
      238
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "agency;",
    "bbox": [
      111,
      243,
      173,
      256
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "d) \"Applicable Regulatory Authority\"' means FDA, EMEA and/or other equivalent governmental or regulatory authorities or agencies and any",
    "bbox": [
      112,
      273,
      1000,
      286
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "successors thereto;",
    "bbox": [
      110,
      290,
      260,
      302
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "e) \"Business Day\" means any day on which banking institutions in Boston, Massachusetts and Bubendorf, Switzerland are open for business;",
    "bbox": [
      113,
      322,
      1000,
      334
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "f) \"Campaign\" means a schedule of one or more discrete batches of Product Manufactured in sequence by Supplier without pausing to change",
    "bbox": [
      111,
      353,
      1000,
      367
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "over to manufacture of any other product;",
    "bbox": [
      111,
      370,
      429,
      382
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "g) \"cGMP Requirements\" means the current Good Manufacturing Practices standards required under ICH Q7A guideline and/or any similar",
    "bbox": [
      112,
      401,
      1000,
      414
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "standards of applicable governmental and/or regulatory authorities as defined in the Quality Agreement;",
    "bbox": [
      110,
      417,
      896,
      430
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "h) \"Change of Control\"' means any transaction or series of transactions wherein (a) the voting securities of Supplier outstanding immediately prior",
    "bbox": [
      111,
      450,
      1000,
      462
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such transaction or",
    "bbox": [
      112,
      467,
      1000,
      477
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "transactions; (b) the stockholders or equity holders of Supplier approve a plan of complete liquidation of Supplier, or an agreement for the sale or",
    "bbox": [
      112,
      483,
      1000,
      493
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "disposition by Supplier of all or substantially all of Supplier's assets, other than to an Affiliate; (c) a Third Party becomes the beneficial owner of",
    "bbox": [
      112,
      498,
      1000,
      510
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "fifty percent (50%) or more of the combined voting power of the outstanding securities of Supplier; or (d) substantially all of Supplier's business or",
    "bbox": [
      112,
      514,
      1000,
      526
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "assets which relate to this Agreement are sold or otherwise transferred to a Third Party;.",
    "bbox": [
      110,
      528,
      770,
      543
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "i) \"Chemical Synthesis\"' means established and reliable execution of chemical reactions in order to produce the \"Product\"' by applying chemical and",
    "bbox": [
      113,
      562,
      1000,
      574
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "physical manipulations usually involving one or more reactions;.",
    "bbox": [
      111,
      577,
      594,
      590
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "j) \"Confidential Information' means all written information and data provided by the Parties to each other hereunder and identified as being",
    "bbox": [
      109,
      608,
      1000,
      623
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "\"Confidential' and provided to the recipient, except that the term \"Confidential Information' shall not apply to any information or any portion",
    "bbox": [
      111,
      625,
      1000,
      638
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "thereof which:",
    "bbox": [
      111,
      642,
      219,
      652
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "(i) was known to the recipient or any of its Affiliates, as evidenced by its written records, before receipt thereof under this Agreement;",
    "bbox": [
      202,
      666,
      1000,
      678
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "(ii) is disclosed to the recipient or any of its Affiliates, without obligations of confidentiality, during the Term by a Third Party who has",
    "bbox": [
      202,
      689,
      1000,
      701
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the right to make such disclosure;",
    "bbox": [
      200,
      705,
      456,
      718
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "CONFIDENTIAL",
    "bbox": [
      112,
      736,
      240,
      746
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Page 8 of 49",
    "bbox": [
      1000,
      734,
      1000,
      748
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "bbox": [
      133,
      1000,
      631,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REOUEST. REDACTED MATERIAL IS",
    "bbox": [
      127,
      84,
      1000,
      94
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "NOISSINNON HNNVHMXA NNV SAILINNMIS HHL HLIM ARALVNVHIS CITI NAGN RRH NNV I*   HLIM HIIVN",
    "bbox": [
      192,
      100,
      1000,
      111
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "common control') shall mean: (a) ownership of at least fifty percent (50%) of the equity capital or other ownership interest in or of an entity; (b) the",
    "bbox": [
      111,
      130,
      1000,
      142
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "power to control or otherwise direct the affairs of an entity; (c) in the case of non-stock organizations, the power to control the distribution of",
    "bbox": [
      110,
      144,
      1000,
      159
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "profits of an entity; or (d) such other relationship as, in fact, results in actual control over the management, business, and affairs of an entity;",
    "bbox": [
      112,
      162,
      1000,
      174
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "b) \"Agreement' means this Supply Agreement for the Product, including all Exhibits attached hereto;",
    "bbox": [
      111,
      193,
      871,
      206
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "c) \"Applicable Law\"' means any applicable law, statute, rule, regulation, order, judgment or ordinance of any governmental or regulatory authority or",
    "bbox": [
      113,
      226,
      1000,
      238
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "agency;",
    "bbox": [
      111,
      243,
      173,
      256
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "d) \"Applicable Regulatory Authority\"' means FDA, EMEA and/or other equivalent governmental or regulatory authorities or agencies and any",
    "bbox": [
      112,
      273,
      1000,
      286
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "successors thereto;",
    "bbox": [
      110,
      290,
      260,
      302
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "e) \"Business Day\" means any day on which banking institutions in Boston, Massachusetts and Bubendorf, Switzerland are open for business;",
    "bbox": [
      113,
      322,
      1000,
      334
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "f) \"Campaign\" means a schedule of one or more discrete batches of Product Manufactured in sequence by Supplier without pausing to change",
    "bbox": [
      111,
      353,
      1000,
      367
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "over to manufacture of any other product;",
    "bbox": [
      111,
      370,
      429,
      382
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "g) \"cGMP Requirements\" means the current Good Manufacturing Practices standards required under ICH Q7A guideline and/or any similar",
    "bbox": [
      112,
      401,
      1000,
      414
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "standards of applicable governmental and/or regulatory authorities as defined in the Quality Agreement;",
    "bbox": [
      110,
      417,
      896,
      430
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "h) \"Change of Control\"' means any transaction or series of transactions wherein (a) the voting securities of Supplier outstanding immediately prior",
    "bbox": [
      111,
      450,
      1000,
      462
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such transaction or",
    "bbox": [
      112,
      467,
      1000,
      477
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "transactions; (b) the stockholders or equity holders of Supplier approve a plan of complete liquidation of Supplier, or an agreement for the sale or",
    "bbox": [
      112,
      483,
      1000,
      493
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "disposition by Supplier of all or substantially all of Supplier's assets, other than to an Affiliate; (c) a Third Party becomes the beneficial owner of",
    "bbox": [
      112,
      498,
      1000,
      510
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "fifty percent (50%) or more of the combined voting power of the outstanding securities of Supplier; or (d) substantially all of Supplier's business or",
    "bbox": [
      112,
      514,
      1000,
      526
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "assets which relate to this Agreement are sold or otherwise transferred to a Third Party;.",
    "bbox": [
      110,
      528,
      770,
      543
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "i) \"Chemical Synthesis\"' means established and reliable execution of chemical reactions in order to produce the \"Product\"' by applying chemical and",
    "bbox": [
      113,
      562,
      1000,
      574
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "physical manipulations usually involving one or more reactions;.",
    "bbox": [
      111,
      577,
      594,
      590
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "j) \"Confidential Information' means all written information and data provided by the Parties to each other hereunder and identified as being",
    "bbox": [
      109,
      608,
      1000,
      623
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "\"Confidential' and provided to the recipient, except that the term \"Confidential Information' shall not apply to any information or any portion",
    "bbox": [
      111,
      625,
      1000,
      638
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "thereof which:",
    "bbox": [
      111,
      642,
      219,
      652
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(i) was known to the recipient or any of its Affiliates, as evidenced by its written records, before receipt thereof under this Agreement;",
    "bbox": [
      202,
      666,
      1000,
      678
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(ii) is disclosed to the recipient or any of its Affiliates, without obligations of confidentiality, during the Term by a Third Party who has",
    "bbox": [
      202,
      689,
      1000,
      701
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "the right to make such disclosure;",
    "bbox": [
      200,
      705,
      456,
      718
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "CONFIDENTIAL",
    "bbox": [
      112,
      736,
      240,
      746
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Page 8 of 49",
    "bbox": [
      1000,
      734,
      1000,
      748
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: PARATEK PHARMACEUTICALS, INC., 10-K/A, 5/5/2017",
    "bbox": [
      133,
      1000,
      631,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  }
]